Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an alpha1-adrenoceptor blocker

HANDLE Web Site Open Access

Bibliographic Information

Other Title
  • 夜間頻尿を有するα1アドレナリン受容体遮断薬投与中の前立腺肥大症患者に対する塩酸フラボキサートの有効性の検討
  • ヤカン ヒンニョウ オ ユウスル アルファ 1 アドレナリン ジュヨウタイ シャダンヤク トウヨチュウ ノ ゼンリツセン ヒダイショウ カンジャ ニ タイスル エンサン フラボキサート ノ ユウコウセイ ノ ケントウ

Search this article

Abstract

We examined the effectiveness of supplemental administration of flavoxate hydrochloride in patients with benign prostatic hyperplasia (BPH) whose nocturia was not adequately relieved by an alpha1-adrenoceptor blocker. Fifty-two patients who had two or more nocturnal micturition after administration of tamsulosin hydrochloride or naftopidil for 4 weeks or more received 400-600 mg of flavoxate hydrochloride in addition to an alpha1-adrenoceptor blocker for another 8-12 weeks. With supplemental administration of flavoxate hydrochloride, significant improvement was observed in the number of nocturnal micturition, total International Prostate Sympton Score, quality of life score and BPH impact index. No significant change was observed in the voided volume, Qmax, voiding time and residual urine volume. Supplemental administration of flavoxate hydrochloride is therefore effective for the improvement of nocturia and QOL in BPH patients resistant to an alpha1-adrenoceptor blocker.

Journal

  • Hinyokika Kiyo

    Hinyokika Kiyo 54 (3), 173-177, 2008-03

    泌尿器科紀要刊行会

Keywords

Details 詳細情報について

Report a problem

Back to top